JOURNAL OF CLINICAL ONCOLOGY

Physical Activity and Survival After Colorectal Cancer Diagnosis

Jeffrey A. Meyerhardt, Edward L. Giovannucci, Michelle D. Holmes, Andrew T. Chan, Jennifer A. Chan, Graham A. Colditz, and Charles S. Fuchs

A B S T R A C T

Purpose

Physically active individuals have a lower risk of developing colorectal cancer but the influence of exercise on cancer survival is unknown.

Patients and Methods

By a prospective, observational study of 573 women with stage I to III colorectal cancer, we studied colorectal cancer–specific and overall mortality according to predefined physical activity categories before and after diagnosis and by change in activity after diagnosis. To minimize bias by occult recurrences, we excluded women who died within 6 months of their postdiagnosis physical activity assessment.

Results

Increasing levels of exercise after diagnosis of nonmetastatic colorectal cancer reduced cancerspecific mortality (*P* for trend = .008) and overall mortality (*P* for trend = .003). Compared with women who engaged in less than 3 metabolic equivalent task [MET] -hours per week of physical activity, those engaging in at least 18 MET-hours per week had an adjusted hazard ratio for colorectal cancer–specific mortality of 0.39 (95% CI, 0.18 to 0.82) and an adjusted hazard ratio for overall mortality of 0.43 (95% CI, 0.25 to 0.74). These results remained unchanged even after excluding women who died within 12 and 24 months of activity assessment. Prediagnosis physical activity was not predictive of mortality. Women who increased their activity (when comparing prediagnosis to postdiagnosis values) had a hazard ratio of 0.48 (95% CI, 0.24 to 0.97) for colorectal cancer deaths and a hazard ratio of 0.51 (95% CI, 0.30 to 0.85) for any-cause death, compared with those with no change in activity.

Conclusion

Recreational physical activity after the diagnosis of stages I to III colorectal cancer may reduce the risk of colorectal cancer–specific and overall mortality.

J Clin Oncol 24:3527-3534. © 2006 by American Society of Clinical Oncology

INTRODUCTION

In both prospective¹⁻¹¹ and retrospective¹²⁻²⁰ studies, physical activity is associated with a significant likelihood of developing colorectal cancer. The International Agency for Research on Cancer concluded that the evidence supports a causal relation between inactivity and colorectal cancer risk.²¹ However, it is largely unknown whether exercise influences survival of patients with established cancer.^{22,23}

Cancer patients often inquire about the utility of lifestyle changes beyond standard therapies.²⁴ Recent data suggest that physically active breast cancer survivors experience a superior survival compared with those who are more sedentary.²⁵ In a recent study of stage III colon cancer patients participating in an adjuvant chemotherapy trial, increasing postdiagnosis physical activity was associated with significant reductions in cancer recurrence and mortality.²² In the latter study, because data on activity before diagnosis were not available, the relative influence of prediagnosis and postdiagnosis exercise or change in activity could not be assessed.

We studied the impact of recreational physical activity among women with local and regional colorectal cancer who were participating in a large, prospective cohort study that was initiated before cancer diagnosis (the Nurses' Health Study).

PATIENTS AND METHODS

Study Population

In 1976, the Nurses' Health Study (NHS) cohort was established when 121,700 female registered nurses

From the Division of Medical Oncology, Dana-Farber Cancer Institute; Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Harvard School of Public Health; Department of Medicine, Massachusetts General Hospital, Boston, MA.

Submitted February 8, 2006; accepted March 23, 2006; published online ahead of print at www.jco.org on July 5, 2006.

Supported in part by a K07 award from the National Cancer Institute (Grant No. K07CA097992-01A1) and an American Society of Clinical Oncology Career Development Award (J.A.M.). The Nurses' Health Study is supported in part by Grant No. P01CA087969 from the National Cancer Institute.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Address reprint requests to Jeffrey A. Meyerhardt, MD, MPH, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115; e-mail: jmeyerhardt@ partners.org.

© 2006 by American Society of Clinical Oncology

0732-183X/06/2422-3527/\$20.00

DOI: 10.1200/JCO.2006.06.0855

Meyerhardt et al

answered a mailed questionnaire on risk factors for cancer and cardiovascular disease.^{26,27} Every 2 years, participants receive follow-up questionnaires to update information on potential risk factors and report new cancer and disease diagnoses. This study was approved by the Human Subjects Committee at Brigham and Women's Hospital.

Measurement of Colon Cancer

On each biennial follow-up questionnaire, participants were asked whether they had had a diagnosis of colorectal cancer during the prior 2 years. When a participant (or next of kin for decedents) reported colorectal cancer, we sought permission to obtain records and pathology reports. Study physicians, blinded to exposure data, reviewed all records related to colorectal cancer and recorded stage, histology, and tumor location. For nonresponders, we searched the National Death Index to discover deaths and ascertain any diagnosis of colorectal cancer that contributed to death or was a secondary diagnosis. We estimate that 96% of the cases of colorectal cancer were identified through these various methods.²⁸ The individuals in this analysis were NHS participants with stage I to III colorectal cancer diagnosed between 1986 (when physical activity was first assessed) and 2002.

Measurement of Mortality

Women were observed until death or June 2004, whichever came first. Ascertainment of deaths included reporting by the family or postal authorities. In addition, the names of persistent nonresponders were searched in the National Death Index.²⁹ The cause of death was assigned by physicians blinded to exposures. In the case of a woman who died as a result of colorectal cancer not previously reported, we obtained medical records of the colorectal cancer diagnosis after permission from next of kin. More than 98% of deaths in the NHS have been identified by these methods. 30

Exclusions

Women were excluded if they presented with metastatic colorectal cancer at time of initial diagnosis or were diagnosed with any other cancer (other than nonmelanoma skin cancer) within 3 years of their colorectal cancer. Moreover, to minimize bias by occult recurrence or other undiagnosed major illnesses, we excluded women who died within 6 months of their postdiagnosis physical activity assessment. There were 573 women eligible for analysis.

Exposure Assessment

We assessed leisure-time physical activity in metabolic equivalent task (MET) -hours per week beginning in 1986, as briefly described.^{2,25} Participants reported duration of participation (range, 0 to 11 or more hours per week) in walking (along with usual pace), jogging, running, bicycling, swimming laps, racket sports, other aerobic exercises, lower intensity exercise (yoga, toning, stretching), or other vigorous activities.

Although we only included women with stage I to III cancer, we presumed that those who eventually died as a result of colorectal cancer had metastatic disease before death. To avoid bias due to declining activity immediately before and after diagnosis of metastatic cancer, physical activity was not updated (thereby a single prediagnosis and single postdiagnosis measurement was determined).

Each activity on the questionnaire was assigned a MET score.³¹ One MET is the energy expenditure for sitting quietly. MET scores are defined as the ratio of the metabolic rate associated with specific activities divided by the

		Pre (ME	ediagnosis Acti T-hours per w	vity reek)		Postdiagnosis Activity (MET-hours per week)					
Characteristic	< 3	3-8.9	9-17.9	≥ 18	P^*	< 3	3-8.9	9-17.9	≥ 18	P^*	
No. of patients	142	152	118	161		167	146	97	144		
Median age, years	65	65	63	66	.12	65	65	64	64	.33	
Body mass index											
Mean, kg/m ²	27.1	27.4	26.4	25.8	.03	27.4	27.0	26.2	25.3	.14	
Change	—	—	_	—		0.3	-0.2	0.8	0.2	.37	
Stage of disease, %					.36					.27	
1	32	27	34	34		24	35	38	37		
II	38	34	34	39		39	37	35	32		
III	30	39	32	27		37	28	27	31		
Site of disease, %					.48					.33	
Colon	81	82	85	76		77	85	78	80		
Rectal	19	18	15	24		23	15	22	20		
Grade of differentiation, %					.17					.007	
Well	19	17	12	17		12	20	5	23		
Moderate	59	64	74	64		70	66	69	55		
Poor/undifferentiated	16	13	9	10		15	9	13	11		
Unknown	6	6	5	9		3	5	13	11		
Smoking status, %					.02					.05	
Never smoker	41	42	48	45		44	42	42	50		
Past smoker	36	43	41	48		44	46	51	47		
Current smoker	23	15	11	7		12	12	7	3		
Year of diagnosis, %					.006					.47	
Prior to 1990	27	23	20	12		16	25	19	21		
1990-1995	29	37	37	34		40	32	36	33		
After 1995	44	40	43	54		44	43	45	46		
Chemotherapy					.26					.82	
Reported "no"	12	16	12	21		17	15	14	15		
Reported "yes"	9	11	11	13		8	14	9	11		
Unknown	79	73	77	66		75	71	77	74		

Abbreviation: MET, metabolic equivalent task.

*By χ^2 test, except age, body mass index, and weight change (which were tested with Wilcoxon rank sum).

Postdiagnosis Activity (MET-hours per week; No n = 554) Eve		Colorectal Cancer-Specific Mortality							Overall Mortality						
		No. of Patients at Risk	Una	djusted	Adj	Adjusted*		No. of	Unadjusted		Adjusted*				
	No. of Events		Hazard Ratio	95% CI	Hazard Ratio	95% CI	No. of Events	Patients at Risk	Hazard Ratio	95% CI	Hazard Ratio	95% CI			
< 3	29	167	Referent		Referent		47	167	Referent		Referent				
3-7.9	21	146	0.78	0.45 to 1.38	0.92	0.50 to 1.69	37	146	0.83	0.54 to 1.27	0.77	0.48 to 1.23			
9-17.9	11	97	0.61	0.31 to 1.23	0.57	0.27 to 1.20	16	97	0.53	0.30 to 0.93	0.50	0.28 to 0.90			
≥ 18	11	144	0.41	0.20 to 0.82	0.39	0.18 to 0.82	21	144	0.47	0.28 to 0.78	0.43	0.25 to 0.74			
P for trend			01		008				003		003				

Abbreviation: MET, metabolic equivalent task.

*Adjusted for body mass index, stage of disease (I, II, III), grade of tumor differentiation, colon or rectal primary, age at diagnosis, year of diagnosis, receipt of chemotherapy (yes, no, unknown), time from diagnosis to physical activity measurement, change in body mass index before and after diagnosis, smoking status (current, past, never).

resting metabolic rate. The values from the individual activities were summed for a total MET-hours per week score. Categories of MET-hours per week were predefined as less than 3, 3 to 8.9, 9 to 17.9, 18 or more, to correspond to the equivalent of less than 1, 1 to less than 3, 3 to less than 6, 6 or more hours per week of walking at an average pace, consistent with prior analyses.³² Our activity questionnaire has been validated previously against activity diaries.^{33,34}

For analyses of prediagnosis physical activity, the response from the immediate prior survey was used (median, 6 months before diagnosis). If a response were missing, one previous assessment would be carried forward; otherwise, the patient was not included in those analyses. For postdiagnosis analyses, the first physical activity assessment collected at least 1 year but no more than 4 years after diagnosis (median, 22 months) was used to avoid assessment during the period of active treatment. For change in activity, patients who changed from a higher to lower category before and after diagnosis, respectively, were categorized as decreasing activity, patients who changed from a lower to higher category were categorized as increasing activity, and patients who remained in the same category were categorized as no change.

Covariates

Stage of disease, grade of tumor differentiation, year of diagnosis, and location of tumor were extracted from the medical record. Beginning in 1993,

women were asked methods of treatment in a supplemental questionnaire. The time interval between cancer diagnosis and assessment of activity was also adjusted for in these analyses. Body mass index (BMI) and smoking status (current, past, or never) were also taken from the biennial questionnaire at the time of the respective physical activity assessment.

Statistical Analyses

Cox proportional hazards models were used to calculate hazard ratios (HRs) of death or death as a result of colorectal cancer, adjusted for other risk factors for cancer survival. In the main analysis, death as a result of colorectal cancer was the primary end point and deaths as a result of other causes were censored. In secondary analyses, death as a result of any cause was the end point. The primary exposure of interest was physical activity after the diagnosis of colorectal cancer. In addition, we examined prediagnosis activity and change in physical activity. For the analyses of postdiagnosis physical activity and change in activity assessment to either death or June 2004. In the analyses of physical activity before diagnosis, participants were observed from the date of diagnosis of colorectal cancer to either death or June 2004. The two-tailed *P* value for the linear trend test across categories was calculated by using the median value of each category as a continuous variable, consistent with prior studies.^{2,25} Tests of interactions between physical activity categories



Fig 1. Cumulative incidence curve of colorectal cancer–specific deaths by level of postdiagnosis physical activity. MET, metabolic equivalent task.





Fig 2. Kaplan and Meier curve of overall survival by level of postdiagnosis physical activity. MET, metabolic equivalent task.

and potential effect modifiers were assessed by entering in the model the cross product of the median of each physical activity category with the dichotomized covariate. All analyses used SAS version 8.0 (SAS Institute Inc, Cary, NC).

RESULTS

Baseline Characteristics by Physical Activity Category

Among the 573 eligible participants with stage I, II, or III colorectal cancer, there were 132 deaths, of which 80 were classified as colorectal cancer–specific deaths. The median time of follow-up from date of diagnosis of women who are alive was 9.6 years (with 95% observed for 5 or more years). Baseline characteristics of the 573 patients are shown according to categories of both prediagnosis and postdiagnosis physical activity (Table 1). In general, women who were more active had a lower BMI and were less likely to have smoked cigarettes.

Physical Activity After Diagnosis

We assessed the influence of physical activity after the diagnosis of colorectal cancer on patient survival (Table 2). Higher postdiagnosis physical activity was associated with a significant reduction in the risk of colorectal cancer–specific and overall mortality, even after adjusting for other predictors of recurrence. Compared with patients who reported less than 3 total MET-hours per week of activity, those reporting 18 or more MET-hours per week had an adjusted HR for cancer-specific mortality of 0.39 (95% CI, 0.18 to 0.82; *P* for trend = .008). Similarly, the adjusted HR for overall mortality was 0.43 (95% CI, 0.25 to 0.74; *P* for trend = .003).

Given that lower levels of physical activity among patients at risk for cancer recurrence could reflect occult cancer recurrence or impending death, we excluded patients who developed cancer recurrence or died within 6 months of completing the physical activity assessment in our primary analyses (n = 8). To address this issue further, we repeated our analyses with a restriction of 12 months. Although statistical power was somewhat diminished, women in the highest category had an HR of 0.54 (95% CI, 0.25 to 1.19) for colorectal cancer–specific mortality (*P* for trend = .08) and an HR of 0.51 (95% CI, 0.29 to 0.91) for overall mortality (*P* for trend = .02), compared with the least active women. If we extend this restriction period further to 2 years, the relationship continued to be evident, with an HR of 0.36 (95% CI, 0.12 to 1.13) for colorectal cancer–specific mortality (*P* for trend = .05) and an HR of 0.39 (95% CI, 0.20 to 0.78) for overall mortality (*P* for trend = .01).

For the analysis of 5-year survival, activity levels were collapsed into three categories (< 3, 3 to 17.9, and ≥ 18 MET-hours per week) based on the results described above (Figs 1 and 2). Of note, follow-up in this analysis begins at the time of completion of the questionnaire that assessed physical activity to reduce bias rather than the date of diagnosis of colorectal cancer, as is typically derived for studies for adjuvant chemotherapy. Nonetheless, the proportion of patients with colorectal cancer–specific deaths at 5 years (Fig 1) was 14.1% for patients who engaged in less than 3 MET-hours per week, 14.4% for patients who engaged in 18 or more MET-hours per week (*P* logrank = .004). There was also a statistically significant difference in overall survival across physical activity tertile (P = .02, Fig 2).

We examined the influence of postdiagnosis physical activity across strata of other predictors of cancer recurrence and mortality (Table 3). The inverse relation between postdiagnosis physical activity and cancer-specific mortality remained largely unchanged across strata of BMI, age, pathologic stage, site of disease, or year of diagnosis.

Characteristic			3-8.9			9-17.9		≥ 18		
	No. of Patients	< 3	Hazard Ratio	95% CI	Hazard Ratio	95% CI	Hazard Ratio	95% CI	P for Trend	P Interaction
Body mass index, kg/m ²										.08
≤ 25	233	Referent	0.88	0.29 to 2.72	1.05	0.30 to 3.70	0.12	0.02 to 0.76	.02	
> 25	292	Referent	0.74	0.34 to 1.64	0.40	0.15 to 1.11	0.45	0.19 to 1.10	.08	
Age, years										.96
≤ 65	269	Referent	0.80	0.33 to 1.93	0.72	0.28 to 1.84	0.56	0.22 to 1.45	.23	
> 65	256	Referent	0.89	0.38 to 2.10	0.43	0.12 to 1.55	0.15	0.04 to 0.64	.005	
Stage										.84
1/11	360	Referent	0.83	0.34 to 2.05	0.63	0.19 to 2.03	0.35	0.11 to 1.17	.08	
	165	Referent	0.81	0.34 to 1.93	0.68	0.26 to 1.82	0.37	0.14 to 1.00	.05	
Site of disease										.33
Colon	421	Referent	1.18	0.57 to 2.41	1.08	0.48 to 2.43	0.49	0.19 to 1.30	.11	
Rectal	104	Referent	0.54	0.14 to 2.09	_		0.28	0.08 to 0.94	.05	
Year of diagnosis										.43
Before 1995	286	Referent	0.74	0.35 to 1.57	0.73	0.31 to 1.72	0.45	0.17 to 1.15	.11	
After 1995	239	Referent	0.92		0.31		0.30		.06	
				0.33 to 2.53		0.06 to 1.49		0.08 to 1.17		

NOTE. Adjusted for body mass index, stage of disease (I, II, III), grade of tumor differentiation, colon or rectal primary, age at diagnosis, year of diagnosis, receipt of chemotherapy (yes, no, unknown), time from diagnosis to physical activity measurement, change in body mass index, smoking status (current, past, never). Abbreviation: MET, metabolic equivalent task.

Physical Activity Before Diagnosis

In contrast to postdiagnosis physical activity, physical activity before diagnosis (Table 4) was not significantly associated with either cancer-specific or overall mortality. When we adjusted for prediagnosis physical activity as well as other predictors of cancer survival, increasing postdiagnosis physical activity was still associated with a significant reduction in both colorectal cancer–specific mortality (*P* for trend = .02) as well as overall mortality (*P* for trend = .002).

Change in Physical Activity

For participants with a prediagnosis and postdiagnosis activity measurement, we calculated change in physical activity based on the difference in exercise categories at those two time points (Fig 3). Compared with women who did not materially change their activity level (n = 203), women who increased their activity (n = 144) had an adjusted HR of 0.48 (95% CI, 0.24 to 0.97) for colorectal cancerspecific mortality and an adjusted HR of 0.51 (95% CI, 0.30 to 0.85) for overall mortality. In contrast, women who decreased their activity level (n = 176) experienced a modest, though nonsignificant, increase in both cancer-specific (HR, 1.32; 95% CI, 0.74 to 2.34) and overall mortality (HR, 1.23; 95% CI, 0.79 to 1.91).

To better characterize this relationship, we subdivided the categories of steady level of activity and increased activity. For patients with no change in activity, we divided participants into those engaging in less than 9 MET-hours per week (152 of 523 participants) and greater than 9 MET-hours per week (51 of 523 participants). For women who increased their activity levels, we defined two populations, those who started with less than 9 MET-hours per week and increased at least one category (102 of 523 participants) and those who started with at least 9 MET-hours per week and increased activity (42 of 523 participants). Compared with relatively sedentary patients with no change in activity, patients who increased their activity (irregardless of prediagnosis) and patients who were consistently active (at least 9 MET-hours per week) had improvements in colorectal cancer– specific mortality and overall mortality (Table 5).

DISCUSSION

In our analyses, women who were physically active after the diagnosis of nonmetastatic colorectal cancer experienced a significantly decreased risk of colorectal cancer–specific death as well as death from



Fig 3. Impact of change of physical activity before and after colorectal cancer diagnosis. *Compared with no change. Adjusted for body mass index, stage of disease (I, II, III), grade of tumor differentiation, colon or rectal primary, age at diagnosis, year of diagnosis, receipt of chemotherapy (yes, no, unknown), time from diagnosis to physical activity measurement, change in body mass index, smoking status (current, past, never).

any cause. Interestingly, level of activity before diagnosis did not influence cancer-specific or overall survival. Colorectal cancer patients who increased their activity from their levels before diagnosis had an approximately 50% reduction in both colorectal cancer–specific and all-cause mortality.

Physical activity has been shown consistently to reduce colon cancer incidence.¹⁻²⁰ Although the mechanism is unclear, the association with sedentary lifestyle and hyperinsulinemia is a potential etiology.³⁵⁻³⁷ Insulin and the insulinlike growth factor family have been associated with enhanced tumor growth and antiapoptosis,³⁵ and colon cancer risk is elevated in individuals with higher circulating levels of insulin or C-peptide (a marker of insulin secretion) and insulinlike growth factor-1.³⁸⁻⁴³ Colon cancer recurrences are believed to be growth of micrometastases. Thus, an environment that allows such microscopic tumors to proliferate could be detrimental. Whether insulinlike factors or other mechanisms potentially linked to physical activity would affect this environment is unknown.

	Tal	ble 4. Colo	rectal Canc	er–Specific an	d Overall N	lortality by Lev	vel of Phy	sical Activ	ity Prior to	Diagnosis			
		Сс	olorectal Ca	ncer–Specific	Mortality		Overall Mortality						
Prediagnosis Activity		No. of	Una	djusted	Ad	justed*		No. of	Una	djusted	Adj	usted*	
(MET-hours per week; n = 573)	No. of Events	Patients at Risk	Hazard Ratio	95% CI	Hazard Ratio	95% CI	No. of Events	Patients at Risk	Hazard Ratio	95% CI	Hazard Ratio	95% CI	
< 3	22	142	Referent		Referent		36	142	Referent		Referent		
3-8.9	22	152	0.92	0.51 to 1.65	0.83	0.45 to 1.53	34	152	0.87	0.54 to 1.38	0.85	0.52 to 1.37	
9-17.9	19	118	1.02	0.55 to 1.88	1.05	0.56 to 1.99	31	118	1.02	0.63 to 1.64	1.14	0.69 to 1.87	
≥ 18	17	161	0.70	0.37 to 1.31	0.86	0.44 to 1.67	31	161	0.82	0.50 to 1.32	0.95	0.57 to 1.59	
P for trend			.26		.81				.50		.92		

Abbreviation: MET, metabolic equivalent task.

*Adjusted for body mass index, stage of disease (I, II, III), grade of tumor differentiation, colon or rectal primary, age at diagnosis, year of diagnosis, receipt of chemotherapy (yes, no, unknown), time from diagnosis to physical activity measurement, change in body mass index, smoking status (current, past, never).

Meyerhardt et al

		Colorectal Cancer-S	pecific Mortality	Overall Mo	ortality	
Activity Level (MET-hours per week)	No. of Patients	Adjusted Hazard Ratio	95% CI	Adjusted Hazard Ratio	95% CI	
Stable activity < 9	152	Referent		Referent		
Stable activity \geq 9	51	0.33	0.11 to 0.97	0.27	0.09 to 0.80	
Increase activity						
Prediagnosis activity < 9	102	0.26	0.10 to 0.66	0.36	0.19 to 0.67	
Prediagnosis activity \geq 9	42	0.35	0.11 to 1.13	0.62	0.28 to 1.34	

*Adjusted for body mass index, stage of disease (I, II, III), grade of tumor differentiation, colon or rectal primary, age at diagnosis, year of diagnosis, receipt of chemotherapy (yes, no, unknown), time from diagnosis to physical activity measurement, change in body mass index, smoking status (current, past, never).

In a separate cohort of men and women with stage III colon cancer, we reported a similar reduction in disease-free survival among patients physically active after diagnosis.²² The NHS provide provides several complementary advantages. First, given that patients who are more physical active after cancer diagnosis may have been active before diagnosis, we considered the possibility that physically active individuals who do develop colon cancer simply acquire tumors that are biologically less aggressive. However, physical activity levels before diagnosis were not predictive of cancer survival. Second, the NHS cohort provided a unique opportunity to explore the relationship of change in activity before and after diagnosis. It should be noted that greater than 50% of women changed levels of physical activity appreciably after diagnosis. Although a decrease in activity was not significantly associated with survival, increases in activity did seem to confer a significantly improved survival. The magnitude of benefit of increasing activity seemed similar in women who were both relatively inactive and more active before diagnosis. These analyses also demonstrate that women who were at a relatively higher level of activity before diagnosis should at least maintain such activity, but do not necessarily need to increase beyond that level. Nonetheless, because we do not know the reasons why these women increased their activity levels, these findings need to be confirmed.

Beyond cause of mortality, data on cancer recurrences were not available in this cohort. Nonetheless, given that median survival for metastatic colorectal cancer was approximately 10 to 12 months during much of the time period of this study,44 colorectal cancer-specific mortality should be a reasonable surrogate for cancer-specific outcomes. Our cohort was restricted to women; it is possible that these findings might not apply to male patients with colorectal cancer. However, we did not observe a sex interaction in our prior study of postdiagnosis activity.²²

In this cohort, data on the treatment are limited. Two thirds of the women had stage I or II disease, in which surgery alone generally would be standard of care. Furthermore, although there are differences in the likelihood of use of adjuvant chemotherapy based on factors such as socioeconomic class, the fairly homogenous nature of this cohort (professional nurses) would likely increase the probability of at least standard therapy.^{45,46} Moreover, as shown in Table 1, chemotherapy use (based on the available data) did not differ according to postdiagnosis physical activity levels. Comorbidities and access to health care may also confound these findings. Given the population studied (professional nurses), we would expect the latter to be relatively diminished. Although comorbidities have been shown to affect mortality in colorectal cancer survivors,47-49 such diseases are less likely to affect disease recurrence and thereby colorectal cancer-specific mortality.

We cannot completely exclude the possibility that lower levels of physical activity may be reflective of other occult predictors for poor prognosis. However, we did not observe any significant associations between physical activity and other predictors of cancer outcome. Our findings remained unchanged after adjusting for potential risk factors for colorectal cancer mortality. Moreover, we found a consistent benefit for physical activity among patients with either stage I/II or stage III disease. Furthermore, we considered the possibility that sick patients (with cancer recurrences and limited survival) will exercise less. To minimize the bias by occult cancer recurrence, we excluded recurrences or deaths within 6 months of the activity assessment in the primary analysis and continued to observe a positive impact of exercise even when extending this restriction to 12 and 24 months. Finally, we would expect few patients to have undetected recurrences over extended periods of time, given the relatively brief natural history of recurrent colon cancer.

Patients who underwent treatment for colorectal cancer may be considered limited in their ability to exercise. However, Arndt et al⁵⁰ reported that 1 year after surgery of the primary tumor, patients with colorectal cancer reported their physical functioning and global quality of life nearly identical to those of a noncancer population. Furthermore, the distribution of levels of exercise in our study does not vary significantly by stage and is similar to that in other reports from the NHS in women without cancer.²

Our results suggest that physical activity after a colorectal cancer diagnosis may lower the risk of death from that disease. This benefit was seen regardless of age, BMI, stage, or site of disease. Along with our prior findings,²² these data suggest that, in addition to surgery and chemotherapy, increasing physical activity may confer additional benefit to patients with colorectal cancer.

REFERENCES

1. Lee IM, Paffenbarger RS Jr, Hsieh C: Physical activity and risk of developing colorectal cancer among college alumni. J Natl Cancer Inst 83:1324-1329, 1991

2. Martinez ME, Giovannucci E, Spiegelman D, et al: Leisure-time physical activity, body size, and colon cancer in women: Nurses' Health Study Research Group. J Natl Cancer Inst 89:948-955, 1997

3. Gerhardsson M, Floderus B, Norell SE: Physical activity and colon cancer risk. Int J Epidemiol 17:743-746, 1988

4. Wu AH, Paganini-Hill A, Ross RK, et al: Alcohol, physical activity and other risk factors for colorectal cancer: A prospective study. Br J Cancer 55:687-694, 1987

5. Thun MJ, Calle EE, Namboodiri MM, et al: Risk factors for fatal colon cancer in a large prospective study. J Natl Cancer Inst 84:1491-1500, 1992

6. Ballard-Barbash R, Schatzkin A, Albanes D, et al: Physical activity and risk of large bowel cancer in the Framingham Study. Cancer Res 50:3610-3613, 1990

 Albanes D, Blair A, Taylor PR: Physical activity and risk of cancer in the NHANES I population. Am J Public Health 79:744-750, 1989

8. Severson RK, Nomura AM, Grove JS, et al: A prospective analysis of physical activity and cancer. Am J Epidemiol 130:522-529, 1989

9. Lynge E, Thygesen L: Use of surveillance systems for occupational cancer: Data from the Danish National system. Int J Epidemiol 17:493-500, 1988

10. Paffenbarger RS Jr, Hyde RT, Wing AL: Physical activity and incidence of cancer in diverse populations: A preliminary report. Am J Clin Nutr 45: 312-317, 1987

11. Giovannucci E, Ascherio A, Rimm EB, et al: Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 122:327-334, 1995

12. Fraser G, Pearce N: Occupational physical activity and risk of cancer of the colon and rectum in New Zealand males. Cancer Causes Control 4:45-50, 1993

13. Longnecker MP, Gerhardsson le Verdier M, Frumkin H, et al: A case-control study of physical activity in relation to risk of cancer of the right colon and rectum in men. Int J Epidemiol 24:42-50, 1995

14. Whittemore AS, Wu-Williams AH, Lee M, et al: Diet, physical activity, and colorectal cancer among Chinese in North America and China. J Natl Cancer Inst 82:915-926, 1990

15. Kune GA, Kune S, Watson LF: Body weight and physical activity as predictors of colorectal cancer risk. Nutr Cancer 13:9-17, 1990

16. Markowitz S, Morabia A, Garibaldi K, et al: Effect of occupational and recreational activity on the risk of colorectal cancer among males: A casecontrol study. Int J Epidemiol 21:1057-1062, 1992

17. Peters RK, Garabrant DH, Yu MC, et al: A case-control study of occupational and dietary factors in colorectal cancer in young men by subsite. Cancer Res 49:5459-5468, 1989

18. Brownson RC, Zahm SH, Chang JC, et al: Occupational risk of colon cancer: An analysis by anatomic subsite. Am J Epidemiol 130:675-687, 1989

19. Kato I, Tominaga S, Matsuura A, et al: A comparative case-control study of colorectal cancer and adenoma. Jpn J Cancer Res 81:1101-1108, 1990

20. Fredriksson M, Bengtsson NO, Hardell L, et al: Colon cancer, physical activity, and occupational

exposures: A case-control study. Cancer 63:1838-1842, 1989

21. Vainio H, Kaaks R, Bianchini F: Weight control and physical activity in cancer prevention: International evaluation of the evidence. Eur J Cancer Prev 11:S94-S100, 2002 (suppl 2)

22. Meyerhardt JA, Heseltine D, Niedzwiecki D, et al: Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: Findings from CALGB 89803. J Clin Oncol 24:3535-3541, 2006

23. Haydon AM, Macinnis R, English D, et al: The effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut 55:62-67, 2006

24. Brown JK, Byers T, Doyle C, et al: Nutrition and physical activity during and after cancer treatment: An American Cancer Society guide for informed choices. CA Cancer J Clin 53:268-291, 2003

25. Holmes MD, Chen WY, Feskanich D, et al: Physical activity and survival after breast cancer diagnosis. JAMA 293:2479-2486, 2005

26. Belanger CF, Hennekens CH, Rosner B, et al: The nurses' health study. Am J Nurs 78:1039-1040, 1978

27. Colditz GA, Manson JE, Hankinson SE: The Nurses' Health Study: 20-year contribution to the understanding of health among women. J Womens Health 6:49-62, 1997

28. Giovannucci E, Colditz GA, Stampfer MJ, et al: A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. women. J Natl Cancer Inst 86:192-199. 1994

29. Sathiakumar N, Delzell E, Abdalla O: Using the National Death Index to obtain underlying cause of death codes. J Occup Environ Med 40:808-813, 1998

30. Stampfer MJ, Willett WC, Speizer FE, et al: Test of the National Death Index. Am J Epidemiol 119:837-839, 1984

31. Ainsworth BE, Haskell WL, Leon AS, et al: Compendium of physical activities: Classification of energy costs of human physical activities. Med Sci Sports Exerc 25:71-80, 1993

32. Colditz GA, Feskanich D, Chen WY, et al: Physical activity and risk of breast cancer in premenopausal women. Br J Cancer 89:847-851, 2003

33. Wolf AM, Hunter DJ, Colditz GA, et al: Reproducibility and validity of a self-administered physical activity questionnaire. Int J Epidemiol 23:991-999, 1994

34. Chasan-Taber S, Rimm EB, Stampfer MJ, et al: Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals. Epidemiology 7:81-86, 1996

35. Sandhu MS, Dunger DB, Giovannucci EL: Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 94:972-980, 2002 **36.** Kaaks R, Lukanova A: Energy balance and cancer: The role of insulin and insulin-like growth factor-I. Proc Nutr Soc 60:91-106, 2001

37. Giovannucci E: Insulin, insulin-like growth factors and colon cancer: A review of the evidence. J Nutr 131:3109S-3120S, 2001

38. Schoen RE, Tangen CM, Kuller LH, et al: Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 91: 1147-1154, 1999

39. Kaaks R, Toniolo P, Akhmedkhanov A, et al: Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 92:1592-1600, 2000

40. Palmqvist R, Stattin P, Rinaldi S, et al: Plasma insulin, IGF-binding proteins-1 and -2 and risk of colorectal cancer: A prospective study in northern Sweden. Int J Cancer 107:89-93, 2003

41. Palmqvist R, Hallmans G, Rinaldi S, et al: Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: A prospective study in northern Sweden. Gut 50:642-646, 2002

42. Ma J, Pollak MN, Giovannucci E, et al: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGFbinding protein-3. J Natl Cancer Inst 91:620-625, 1999

43. Manousos O, Souglakos J, Bosetti C, et al: IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer 83:15-17, 1999

44. Meyerhardt JA, Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med 352:476-487, 2005

45. VanEenwyk J, Campo JS, Ossiander EM: Socioeconomic and demographic disparities in treatment for carcinomas of the colon and rectum. Cancer 95:39-46, 2002

46. Schrag D, Cramer LD, Bach PB, et al: Influence of hospital procedure volume on outcomes following surgery for colon cancer. JAMA 284:3028-3035, 2000

47. Payne JE, Meyer HJ: The influence of other diseases upon the outcome of colorectal cancer patients. Aust N Z J Surg 65:398-402, 1995

48. Yancik R, Wesley MN, Ries LA, et al: Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: A population-based study. Cancer 82:2123-2134, 1998

49. Piccirillo JF, Tierney RM, Costas I, et al: Prognostic importance of comorbidity in a hospitalbased cancer registry. JAMA 291:2441-2447, 2004

50. Arndt V, Merx H, Stegmaier C, et al: Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: A population-based study. J Clin Oncol 22:4829-4836, 2004

Authors' Disclosures of Potential Conflicts of Interest

The authors indicated no potential conflicts of interest.

Author Contributions

Conception and design: Jeffrey A. Meyerhardt, Edward L. Giovannucci, Michelle D. Holmes, Charles S. Fuchs Financial support: Jeffrey A. Meyerhardt, Edward L. Giovannucci, Graham A. Colditz, Charles S. Fuchs Administrative support: Jeffrey A. Meyerhardt Provision of study materials or patients: Edward L. Giovannucci, Graham A. Colditz Collection and assembly of data: Edward L. Giovannucci, Graham A. Colditz, Charles S. Fuchs Data analysis and interpretation: Jeffrey A. Meyerhardt, Michelle D. Holmes, Andrew T. Chan, Jennifer A. Chan, Graham A. Colditz, Charles S. Fuchs Final approval of manuscript: Jeffrey A. Meyerhardt, Edward L. Giovannucci, Michelle D. Holmes, Andrew T. Chan, Jennifer A. Chan, Graham A. Colditz, Charles S. Fuchs